# IMRAD: What goes into each section


Source: http://www.jpgmonline.com/documents/author/24/2\_Aggarwal\_10.pdf (Journal of Postgraduate Medicine - Online)

# Parts of an Essay

Beginning

Main Body

End



# Parts of a Paper: IMRAD


Introduction

**M** Methods

**R** Results

**a** and

**D** Discussion



# Bradford Hill's Questions

Introduction Why did you start?

Methods What did you do?

**R**esults What did you find?

and

**D**iscussion What does it all mean?

# Introduction (Why did you start?)

Rationale of the study

 Supply sufficient background information to allow a reader to understand and evaluate the results of present study without referring to previous publications on the topic

- Review pertinent literature to orient the reader
- Define lacunae and shortcomings in current state of knowledge
- Provide rationale for the current study
  - What gap in knowledge did you try to fill?
  - What controversy did you try to resolve?
- State aim of the study

- Brief, clear, to the point
- Written mostly in present tense
- May state the study group, study design and methods used
  - (How and why are these better than those of previous studies)
- May state the principal result/conclusion

- Key references supporting background information provided in this section
- Refer to your previous preliminary work
- Refer to your own closely related papers appearing elsewhere
- Define any specialized terms, definitions or abbreviations you intend to use

# Introduction: Common problems

- Historical details
- Too long
- Too general and vague
- Imitative
- Contains 'discussion' material

# Introduction: Example

For investigations done in the emergency laboratory costs are higher<sup>1</sup> and quality more difficult to ensure.<sup>2</sup> These investigations are also more frequently misused.<sup>3</sup> We therefore decided to study which investigations really contributed to clinical decision making in acute care medicine.

We wish to suggest a structure for the salt of deoxyribose nucleic acid (D.N.A.). This structure has novel features which are of considerable biological importance.

Watson JD, Crick FHC. A structure for deoxyribose nucleic acid. Nature 1953; 171: 737-8.

# Methods (What did you do?)

(Materials and Methods; Patients and Methods)

Who? What? When? Where? How? Why?

Study design

Study material (what did you work with?)

What was done to the study material (intervention)?

How was the effect assessed (outcome measures)?

Analysis and statistical methods

Ethical considerations

(Sections and subsections help)

## Methods

# Study design

Case-control, cohort, cross-sectional

Prospective, retrospective

Controlled, uncontrolled

Randomized, non-randomized

Open, Blinded (single or double)

# Methods

## What did you work with?

Humans, animals, in vitro preparation

Volunteers/patients

Controls

#### How selected?

Eligibility, definitions, inclusion/exclusion criteria

Population-based, hospital-based

Particular age group, gender, SE status

Consecutive or not

Urban, rural, suburban

# Methods

## Randomization/blinding: any violations

#### Intervention

Drugs, chemicals (amount, route, frequency, source)

Techniques and procedures, modifications

Equipment used (model, settings)

Compliance

#### Measurements

By whom? Was it objective and accurate?

How often? Repetitions --> how averaged?

Who administered the questionnaire? Where?

# Methods (What did you actually do?)

# Endpoints and outcome: how assessed

Response, partial response, failure, relapse

Mild, moderate, severe

Side-effects

Withdrawals and dropouts

## Sample size calculation

# Statistical analysis

Hypothesis testing: How? Are assumptions OK?

Multiple testing. Software used

Intention-to-treat *versus* per protocol

# Results (What did you find?)

```
Results of all experiments in natural order in subsections similar to methods
```

Text, tables and figures do not duplicate

Statistical analysis (RR, 95% CI)

### Results

### Data collection and recruitment (Response rate)

# Study group

Number, baseline characteristics Drop-outs, withdrawals Absent data on some subjects

# Key findings

Primary outcome measures

# Secondary findings

Secondary outcome measures Subgroup analyses

## Results

```
What does 56.78 ± 12.34 mean?
What does 16.7% mean?
What is the denominator?
What is
normal, abnormal?
raised, high, low?
Cite all tables/figures in text
```

## Results

Should not include
Any methods
Data for which methods are not included
Interpretation of data (--> discussion)
References

Careful with use of words like significant, random, correlation

# Discussion (What does it mean?)

Recapitulation of major findings Discussion of findings cf. available data Why the difference, why more reliable, etc. Discussion of important minor findings Alternative explanations Strength and pitfalls Implications of the findings Unanswered questions and future research Final summary / conclusion

# Discussion

#### Should not include

History

Repetition of results

Discussion of points other than those generated by the study's data

Unreasonable extrapolation of results

Superlatives

# Discussion: Common pitfalls

- First study in the world/India/Parel ......
- Megalomania
- Emphasizing strengths, not weaknesses
- Reiterating selected results
- Inflating the importance and generalizability of findings
- Going beyond the evidence and drawing unjustified conclusions